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Acute SIVmac infection in macaques is accompanied by high levels of plasma viremia that decline with the appearance of viral im-
munity and is a model for acute HIV disease in man. Despite speciﬁc immune responses, the virus establishes a chronic, persistent
infection. The destruction of CD4+ and CD4− lymphocyte subsets in macaques contributes to viral persistence and suggests the
importanceofmechanismsfordepletingbothinfectedanduninfected(bystander)cells.BystandercellkillingcanoccurwhenFasL
binds the Fas receptor on activated lymphocytes, which include T and B cell subpopulations that are responding to the infection.
Destruction of speciﬁc immune cells could be an important mechanism for blunting viral immunity and establishing persistent
infection with chronic disease. We inhibited the Fas pathway in vivo with a monoclonal antibody against FasL (RNOK203). Here
we show that treatment with anti-FasL reduced cell death in circulating T and B cells, increased CTL and antibody responses to
viral proteins, and lowered the setpoint viremia. By blocking FasL during only the ﬁrst few weeks after infection, we attenuated
SIVmac disease and increased the life span for infected and treated macaques.
Copyright © 2007 Maria S. Salvato et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
In 1991, Amiesen and Capron proposed that inappropri-
ate induction of activation-induced cell death (AICD) was
a major mechanism for depleting CD4+ T cells during
HIV disease [1] and they demonstrated apoptosis in PBMC
from HIV-infected individuals [2]. A molecular mecha-
nism for AICD was demonstrated in 1995, involving FasL
(known then as APO-1) binding to its receptor [3], and
FasL-mediated apoptosis was elevated in PBMC from HIV-
infected individuals [4].
Activation-induced cell death (AICD) is a feature of nor-
mal physiology and can be demonstrated in vitro. T cells that
are stimulated by ligating their T cell receptor (TCR) and
then restimulated a few days later, will die by apoptosis [5].
When AICD aﬀects mature, circulating T cells, it is termed
peripheral deletion and this mechanism can extinguish the
response to a particular antigen by deleting all lymphocyte
clones with that receptor speciﬁcity. Peripheral deletion of-
ten occurs after exposure to superantigens, where we observe
the loss of speciﬁc V-beta T cell subpopulations.
Many viruses and bacteria exploit lymphocyte depletion
mechanisms in order to establish persistent infections. By
eliminating pathogen-speciﬁc immunity, microbes canavoid
detection and elimination. A classic example is lymphocytic
choriomeningitis virus infection in mice. Some strains of
LCMV are acutely lethal, and the CTL response is a major
part of the immune pathology. Nonlethal, persisting strains
of LCMV trigger the deletion of virus-speciﬁc CTL, thus re-
ducing pathology and allowing for chronic infection [6, 7].
We believe that HIV is similar, in that infection promotes
a mechanism for deleting antiviral immune cells. In HIV2 Clinical and Developmental Immunology
disease, immune depletion is not limited to antiviral re-
sponsesandeventuallyspreadstodisruptimmunityagainsta
number of intercurrent pathogens. The result increased sus-
ceptibilitytoopportunisticinfectionsthatbecomemajorfac-
tors in disease and death.
Viral proteins have been implicated in the regulation of T
cell activation and Fas-mediated killing. Both the HIV-1 Tat
and Env proteins can activate cells and induce Fas-mediated
killing [8, 9]. Tat protein activates the Fas ligand promoter
[10], and soluble Tat causes production of FasL and an-
other death ligand (TRAIL) in monocyte/macrophages or
dendritic cells [11–13]. Chemically-inactivated virions trig-
ger both T cell activation and apoptosis [14]. Env glycopro-
tein alone upregulates FasL [15], although it is controversial
whether this occurs with monomeric gp120 or needs CD4
crosslinking. Direct binding to CCR5 also induced FasL[16].
HIV disease is characterized by extensive lymphocyte activa-
tion with elevated expression of Fas receptor (CD95) on a
majority of circulating T cells. These activated cells are killed
when FasL binds [4, 17]. FasL itself is upregulated during
HIV infection [18, 19] and is especially high on antigen-
presenting cells [20, 21] where it is poised to kill CD4+ T
cells during their initial encounter with antigen.
Apoptosis was evident in lymph nodes from macaques
acutely infected with SIV and the proportion of apop-
totic cells was highest for rapid progressors [22]a n dw e
showed that macaques with pre-existing, high levels of FasL-
mediated cytotoxicity for human B lymphoblastoid cell line
(B-LCL) targets, became rapid progressors after SIVmac in-
fection [23]. In the present study, we tested the hypothesis
that FasL-mediated cell death is important for SIV disease in
macaques, by injecting a monoclonal antibody that neutral-
izes FasL [24] during the interval of acute infection.
2. RESULTS
The FasL-speciﬁc, recombinant monoclonal antibody
RNOK203 [24] inhibited MHC-unrestricted cytotoxicity
in vitro (Figure 1(a)) and MHC-unrestricted cytotoxicity
was correlated with the levels of cell surface FasL on PBMC
from virus-na¨ ıve macaques (Figure 1(b)). Pilot studies with
anti-FasL at 4mg/kg showed no noticeable impact on T or
B cell counts in healthy monkeys (not shown). Injection of
RNOK203 into a control (uninfected) macaque caused a
transient decrease in MHC unrestricted cytolysis of human
B-LCL targets (Table 1), with cytotoxicity returning to
normal a few weeks after antibody treatment, compared to
stable levels of B-LCL cytolysis in one macaque treated with
a control IgG and one untreated animal.
We screened rhesus macaques and selected eight animals
(from a total of 19) with both high levels of FasL-mediated,
MHC-unrestrictedcytotoxicity,andelevatedFasLexpression
on PBMC. Based on the potency of RNOK203 for block-
ing FasL-mediated cytotoxicity in vitro, we determined that
4mg/kg body weight was an appropriate single dose for ju-
venile macaques. Selected animals received either anti-FasL
or human IgG1 (isotype control). All animals received ﬁve
intravenous injections of antibody in saline at 1 week before,
thetimeof,then1,2,and3weeksafterSIVinoculation.Each
Table 1: Anti-FasL injection in vivo transiently decreases PBMC
cytotoxicity. The values for speciﬁc lysis in standard conditions are
shown for each specimen at time points between 2 weeks before
infection (−2) to 20 weeks after infection. All the PBMC samples
shown had mean ﬂuorescent intensity (MFI) levels for FasL ranging
from 95–180 as compared to <90 MFI for macaques treated with
anti-FasL and sampled between weeks 2 and 10.
Week −2 2 10 20
RNOK203 24.8 2.1 5.7 22.3
Control IgG 25.2 24.3 22.0 20.2
Untreated 23.8 22.0 21.3 20.9
animalwasinoculatedbyintravenousinjection,with40min-
imal animal infectious doses of SIVmac239 [25]; the time
of virus inoculation was deﬁned as week 0. We conﬁrmed
the impact of anti-FasL in vivo, by a reduction in the fre-
quencyofdyinglymphocytesinblood.AssaysforbothMHC
Class I-restricted CTL activity against the SIV p27 Gag and
virus-binding serum antibodies characterized the impact of
RNOK203 on viral immunity. We measured acute and set-
point plasma viremia to characterize the course of infection;
survival time was also measured.
The frequency of circulating lymphocytes that incorpo-
rate 7-amino actinomycin D was reduced by treatment with
anti-FasL for CD4-positive (Figure 2(a)) and CD8-positive
T cells (Figure 2(b)), and for B cells (Figure 2(c)). Control
macaques showed a sharp increase in the frequency of dying
T and B cells within 1 week after infection; these values in-
creased to peak levels of around 25% for CD4+ T cells, 30%
for CD8+ T cell, and 40% for CD20+ B cells. Anti-FasL-
treated animals had only baseline levels of dying cells until
around 6–8 weeks after SIV infection. Similar results were
obtained with monoclonal antibodies against Annexin V, a
markerforlymphocyteapoptosis(notshown).By8weeksaf-
ter SIVmac infection (Table 2), the IgG-treated (control) an-
imals had a 49% + 8% of starting CD4 cell counts, compared
to an 87% + 36% of starting CD4 T cells in the anti-FasL-
treated group (P =.03 by t test). Similar eﬀects were noted
for CD20+ B cells where control animals had 43% ± 16%
compared to the anti-FasL-treated group which had 116%±
74% of starting B cell counts (P =.03). At 8 weeks, there were
no signiﬁcant diﬀerences in the CD8+ T cell counts among
control and anti-FasL-treated groups.
Lower cell death levels persisted until around 40 weeks
after infection. Acute viremia was similar among treated and
control groups, but RNOK203 lowered the set-point vRNA
levels (from the limit of detection at 103 to 6 × 106 copies
per ml), compared to the range of 3 × 106 to 4 × 107 copies
permLforcontrols.Thus,thereducedlymphocytecelldeath
seen before 40 weeks was associated with lower vRNA, al-
though some treated animals had viremia in the range of
controls.
CTL to p27 Gag protein and virus-binding serum an-
tibodies were measured in treated and control macaques
(Figure 3). With eﬀector to target cell ratios of 50, we ob-
served speciﬁc lysis of around 40% for anti-FasL-treated and
33% for control macaques by 5 weeks after SIV infectionMaria S. Salvato et al. 3
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Figure 1: The anti-FasL monoclonal antibody blocks MHC-unrestricted cytolysis and stains FasL on rhesus PBMC. (Panel A) Anti-FasL,
the humanized NOK2 monoclonal (RNOK203), blocked MHC-unrestricted cytolysis in vitro using rhesus or human PBMC as eﬀectors and
human or rhesus B-LCL targets that expressed SIV envelope glycoprotein (transfected with pCDNA3/SIVenv). The four-hour chromium-
release assay was done in the presence of 1mM EGTA and varying amounts of anti-FasL at an E : T ratio of 50 : 1 as described [23].
Speciﬁc lysis was blocked completely at 20μg/mL of monoclonal antibody (shown) and not with a similar concentration of isotype control
antibody(notshown).Whennoeﬀectorcellswereadded(NoE),therewasnospeciﬁclysisshowingthat20μg/mLanti-FasLdoesnotinduce
cell death on its own. These experiments were done 3 times with rhesus PBMC, 3 times with human PBMC, and 2-3 times cross species
with the same results. The error bars represent the variation in 3 diﬀerent experiments using rhesus cells. (Panel B) MHC-unrestricted
cytolytic activity correlated with the mean ﬂuorescence intensity (MFI) of cell surface FasL on circulating PBMC. PBMC specimensfrom
rhesus macaques were screened by the MHC-unrestricted cytolysis assay as described [23]. Results from 10 rhesus macaques are shown
here. Macaques were divided into high (≥15% speciﬁc lysis) and low (<10% speciﬁc lysis) groups, and stained with the anti-FasL antibody
in an indirect immunoﬂuorescence assay. The individual points, mean values, and standard deviations are shown for animals classiﬁed as
having low or high cytolytic activity. Macaques with high levels of MHC-unrestricted cytolytic activity and correspondingly high levels of
cell surface FasL were selected for this study.
Table 2: Absolute lymphocyte cell counts. Absolute cell counts are given as cells per microliter of blood. Each number is the average of the
absolute counts for 4 animals. The counts in parentheses reﬂect the range of counts seen in 4 animals at that time point. Time is given in
weeks from the start of antibody treatment. Week 0 is the lymphocyte count on the ﬁrst day of treatment, taken before the inoculation with
antibody.
Time group Anti-FasL-treated group IgG-treated (control)
CD4 (range) CD8 (range) CD20 (range) CD4 (range) CD8 (range) CD20 (range)
Wk 0 3185 (4228–2512) 3023 (4409–2612) 1233 (2100–640) 2519 (3002–1079) 2246 (3123–1554) 779 (1021–292)
Wk 8 2630 (3965–1872) 2953 (3794–1721) 1206 (2128–536) 773 (1167–641) 2035 (2681–1567) 331 (579–148)
Wk 20 1450 (2441–1066) 2432 (3244–1063) 998(1247–608) 734(1585–620) 1336(2230–945) 227(349–120)
(Figure 3(a)). These modest diﬀerences were statistically sig-
niﬁcantatweeks15and45(P<.05);deathofcontrolanimals
precludedstatisticalcomparisonsafter45weeks.By24weeks
after SIV infection, all treated animals had virus-binding an-
tibody titers ≥100,000, compared to 1 of 4 animals in the
control group (Figure 3(b)). Overall, there was a modest ef-
fect of anti-FasL on virus-speciﬁc CTL activity, but a pro-
nounced eﬀect on virus-binding antibodies.
Increased viral immunity and lower set-point vRNA lev-
els argue that disease was attenuated after the brief treatment
with RNOK203. The fraction of surviving animals (Figure 4)
showed a signiﬁcant diﬀerence between anti-FasL-treated
animals and control groups. The control group behaved as
expected for intravenous SIVmac239 in rhesus macaques
[28]; half were dead by 42 weeks and all succumbed by
52 weeks. None of the anti-FasL-treated animals were dead
before 60 weeks and the last survivors remained until 102
weeks. The two animals surviving the longest had the low-
est set-point viremia, implying that the impact of RNOK203
on virus replication was linked with disease progression and
survival.
3. DISCUSSION
Some aspects of AIDS pathogenesis remain unsettled. Two
recent papers highlighted the conﬂict between models focus-
ing solely on viral replication as the cause for memory T cell
depletion and disease [29] and models that incorporate both
virus replication and bystander cell killing [30]. It is impor-
tant to remember that virally infected cells are resistant to
death signals delivered by FasL or TNF-related apoptosis-
inducing ligand (TRAIL) [13, 31–34]; these soluble death
ligands are induced during virus infection and would pro-
mote the depletion of uninfected cells to eﬀectively increase4 Clinical and Developmental Immunology
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Figure 2: Inhibition of cell death and reduced plasma vRNA after treatment with anti-FasL. Macaque PBMC specimens were collected 1
week before (−1) and at regular intervals after SIVmac239 infection (that occurred at week 0). The animals were treated with RNOK203 or a
control IgG1 (Sigma #I-3889). Panels (a)–(c) show the proportion of dying (positive for 7-AAD staining) lymphocytes in the CD4+, CD8+,
or CD20+ subsets. Open symbols represent the average values among four macaques treated with control IgG. Closed symbols represent the
averagevaluesamongfourmacaquestreatedwithanti-FasL.Errorbarsshowthestandarderrorofthemeanforeachtimepoint.Theabsolute
cell counts for panels (a)–(c) are summarized in Table 2. Panel D shows the plasma SIVmac vRNA levels for each animal determined by b-
DNA assays (conducted by Bayer Diagnostics, Emeryville, CA). The two animals with lowest set-point RNA were also the two that survived
longest (Figure 4). Open symbols represent control animals and closed symbols represent macaques treated with anti-FasL. The limit of
detection for this assay was 103vRNA copies per mL of plasma.
the proportion of infected cells. Thus, observed increases in
the relative abundance of infected cells may not be explained
solely by virus dissemination.
Bystander cell killing via FasL is likely triggered by high
viremia during acute infection, but numerous examples ar-
gue that virus replication alone is insuﬃcient for disease.
Several macaque species maintain high levels of SIV repli-
cation without evident disease [35, 36]. There are indica-
tions in these models that reduced lymphocyte apoptosis in
vivo and resistance to activation-induced cell death in vitro
can lessen bystander cell killing and prevent disease [37, 38].
SIV-infected cells upregulate FasL and can thereby mediate
the destruction of virus-speciﬁc cytotoxic T cells [34]. At the
same time, SIV-infected cells avoid apoptosis by upregulat-
ing Bcl-2 [33]. These events explain how high FasL-mediated
bystander killing could also lead to high virus loads. The loss
of uninfected cells not only depletes T and B cells respond-
ing to viral antigens, but also impacts gamma/delta [39]a n d
NK T cell [40] populations that comprise critical innate re-
sponses to viral infection and disease. The latter subsets are
not usually infected by HIV-1 and are likely depleted by an
indirect mechanism, consistent with FasL-mediated death of
activated cells.
Mechanisms by which FasL kills activated T and B cells
have been described [41, 42], and it is known that this killing
can be blocked by FasL antagonists [43, 44]. Activation in-
creases the expression of Fas receptor on T and B cells [3]
andevenrestingcellscanbekilledbyhighlevelsofFasL[45].Maria S. Salvato et al. 5
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Figure 3:CellularandhumoralimmuneresponsestoSIVareenhancedbyanti-FasLtreatment.MHC-restrictedCTLtoSIVp27Gagprotein
(Panel A) were measured in a standard 4 hours. 51Cr-release assay [26]. Targets were syngeneic B-LCL (diﬀerent lines for each animal) that
wereeitheruninfectedorinfectedwithVVgagasdescribed[26].Percentspeciﬁclysisatthe50:1eﬀectortotargetratiowasplotted.Themean
and standard errors of the mean (SEM) are shown for four animals treated with anti-FasL (shaded bars) or four control macaques (solid
bars) at the times indicated. The values for CTL activity were consistently higher among macaques treated with anti-FasL compared with
controls, but the diﬀerences were not signiﬁcant at 30 weeks after infection. Virus binding titers (Panel B) were measured by ELISA using
plates coated with p27 Gag antigen as described [27]. Sera from weeks 12 (shaded bars) or 24 (solid bars) were diluted with normal saline, up
to a maximum dilution of 1:100,000. Macaques (A, B, C, D) on the left side of the ﬁgure had been treated with anti-FasL, and macaques (E,
F, G, H) on the right side had been treated with control IgG. Anti-FasL treatment caused a substantial elevation in virus-binding antibodies
in SIV-infected macaques, which have been shown to correlate with reduced disease progression [28].
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Figure 4: Anti-FasL treatment prolongs survival in SIVmac-
infected macaques. The fraction of surviving animals is plotted for
up to 102 weeks after SIVmac239 infection. The thin line shows the
fraction of animals surviving after control IgG treatment and SIV
infection. All control animals died by 52 weeks after SIV infection.
The thick line shows the eﬀect of anti-FasL treatment (anti-FasL) in
extendingsurvivaltimes.Noneoftheanti-FasL-treatedanimalshad
died before 60 weeks after SIV infection, and the last surviving an-
imal lived until 102 weeks. The two longest-lived animals also had
lowest viral loads (Figure 2(d)).
We have considered the simplest role for anti-FasL as an in-
hibitor of T and B cell death, and we documented increases
in T and B cell subsets that are consistent with that role. Our
modelisthatanti-FasLisblocking FasLoncellsurfacesoron
released vesicles and preventing the destruction of eﬀector T
and B cells. The surviving eﬀectors eventually destroy virus-
infected cells and limit virus spread and disease. However,
more complex indirect mechanisms could account for our
results. For example, FasL treatment of B cells causes both
cell death and down-modulation of IgM production by dif-
ferent pathways [46]. Also, cytotoxic CD4 cells can destroy B
cells in a Fas/FasL-dependent manner, but only if the B cells
wereCD40L-activatedandnotiftheywereactivatedthrough
the antigen receptor [47]. Thus, anti-FasL could also be en-
hancing eﬀector functions that are indirectly responsible for
decreases in viral load or increases in B and T cells.
Antiretroviral therapy during acute infection can modu-
latethelong-termconsequencesofSIVinfection[48,49],in-
cluding a reduction in lymphocyte apoptosis [50]. In this in-
terventionstudy,peakacuteviremiawasnotaﬀectedbyanti-
FasL treatment arguing that virus replication was not the
critical factor for disease. An early and transient inhibition
of FasL allowed for increased viral immunity, lower viremia
in some of the treated animals, and longer survival after
SIV infection. In human beings, antiretroviral therapy dur-
ing acute HIV infection [51] was associated with increased
viral immunity but the eﬀect was not durable [52]. With ex-
panding eﬀorts to identify persons with acute HIV infection
throughpopulationscreening[53]andtheneedtotreatchil-
dren acutely infected through vertical transmission, impor-
tant opportunities may emerge for combining antiretroviral
drugs with modulators of cell killing to reduce disease and
prolong the interval for AIDS-free survival.
4. METHODS
4.1. Animalinfectionsandsamplingintervals
Eight rhesus macaques housed at the Wisconsin Regional
PrimateResearchCenter,3-4yearsofage,retrovirusfree,and6 Clinical and Developmental Immunology
foamy-virus free, were selected because they had high MHC-
unrestricted lytic activity [23]. Baseline values for lympho-
cyte subsets, activation markers, and FasL were determined
over3months,thenanimalswereinfectedwith40TCID50of
SIVmac239 as described [28]. Animals were conﬁrmed pos-
itive for infection by two independent virus isolation assays
and tests for SIV viremia. Venous blood samples were col-
lected weekly from 4 weeks before infection to 5 weeks after
infection, then at weeks 7, 10, 12, and 15 after infection, and
then approximately every four weeks until euthanasia. The
percentage of dying cells in CD4+, CD8+,and CD20+ lym-
phocytesubsets,plasmavRNAlevels,MHCClassI-restricted
cytotoxicity, and virus binding antibody titers were deter-
mined among other standard characterizations and daily ob-
servations. Macaques were euthanized when, in the opinion
oftheattendingveterinarian,theyhadenteredaterminaldis-
ease state and euthanasia was required to alleviate unneces-
sary suﬀering. The research protocol wasapproved by the In-
stitutionalAnimalCareandUseCommitteeoftheUniversity
of Wisconsin Graduate School.
4.2. Virusstocksandcelllines
The stock of SIVmac239 was stored at –130◦C at 400
TCID50/mlasthethirdpassageofastockoriginallyobtained
from Dr. Ron Desrosiers [54]. Recombinant vaccinia viruses
(gift from Therion Biologics, Cambridge, MA) were derived
from the NYCBH vaccinia strain and contained either no in-
sert or genes from SIVmac251.
Human B-lymphoblast cell lines (B-LCL) were produced
by transformation of human PBMC with human Epstein
Barr virus (EBV) B95-8 cell supernatant kindly provided
by Dr. W. Sugden. B-LCL were maintained in RPMI-1640
(Gibco, Gaithersburg, MD) supplemented with L-glutamine
(2nM), penicillin (50U/ml), streptomycin (50U/ml), and
10%fetalcalfserum(HarlanSpragueDawley,Madison,WI),
then diluted into wells of 24-well plates and cryopreserved
as B-LCL. Rhesus macaque B-LCL were obtained by trans-
forming rhesus PBMC with Herpes papio from S594 cell su-
pernatants kindly supplied by N. Letvin, and were stored as
viable, frozen cells.
4.3. Antibodiesandanimaltreatments
The monoclonal antibody to surface FasL was RNOK203
[55]. The isotype control antibody was human IgG1 (Sigma
#I-3889) puriﬁed by binding to Protein G agarose beads
(Sigma) and eluting in 100mM glycine HCL (pH 2.7). The
concentrated antibody solution was dialyzed against PBS,
t h e ns t o r e di nb u ﬀer at 5mg/ml. Antibody infusions were
4mg/kg or for a 3kg animal, about 12mg in 2.4mL for each
inoculation. Macaques A, B, C, and D were given anti-FasL
and macaques E, F, G, and H were given the control IgG.
Levels of endotoxin in anti-FasL and control IgG anti-
bodies were less than 13 EndotoxinUnits/mL (approximately
2.5ng/mL determined by an E-toxate kit (Sigma)) and were
similar to levels in normal monkey plasma. To insure the
safety of antibody infusions, each procedure was preceded
by a skin test: 0.2mL of a 1/1000 dilution of the antibody
was inoculated subcutaneously and observed for 10 minutes.
This was negative for all animals. As an additional precau-
tion, all antibody infusions were accompanied by injections
withantihistamine(Benadril)at5mg/kg.Macaqueswerein-
fusedwithanti-FasLorthecontrolantibodyat1weekbefore,
the time of, then 1, 2, and 3 weeks after SIV inoculation for
a cumulative antibody dose of 20mg/kg over a period of 5
weeks.
4.4. Cytolysisandantibodyassays
To measure MHC-unrestricted cytolytic activity, human or
monkey eﬀector cells were incubated with chromium-51
(51Cr)-labeled human B-LCL as described [23]. To measure
SIV-speciﬁccell-mediatedimmunity,eﬀectorsweremacaque
PBMC and targets were syngeneic B-LCL (diﬀerent lines for
each animal) that were either uninfected or infected with
VVgag as described [26], then labeled with 51Cr. Eﬀector
PBMC were isolated from the whole blood of uninfected or
SIV-infected rhesus monkeys by Ficoll-Hypaque density gra-
dient centrifugation, stimulated in vitro with 5μg/ml con-
canavalin A (Sigma, St. Louis, MO) for 3 days followed by
culture in 20U/ml recombinant human interleukin-2 for an
additional 4 days. Standard 4-hour chromium-release as-
says were performed in triplicate in 96-well U-bottom mi-
crotiter plates (Costar, Cambridge, MA) as described pre-
viously [23]. To determine MHC-unrestricted lysis, assays
were done in the presence of 1mM EGTA to exclude xeno-
lysis. Percent speciﬁc lysis was determined with the follow-
ing formula: 100X (experimental release - spontaneous re-
lease)/(maximum release- spontaneous release). Maximum
release was determined by the lysis of targets in 1% Triton
X-100. Spontaneous release was determined by the lysis of
targets in medium without eﬀectors, which was consistently
less than 20% of speciﬁc lysis.
Virus-bindingtitersweremeasuredbyELISAusingplates
coated with p27 Gag antigen as described [27]. Sera from
weeks 12 (shaded bars) or 24 (solid bars) were diluted with
normal saline, up to a maximum dilution of 1 : 100,000. An-
tibodies bound to p27 Gag protein were detected with sec-
ondary antibodies linked to horse radish peroxidase.
4.5. Flowcytometryforsubsetidentiﬁcation
andforapoptosis
CD4+, CD8+, and CD20+ lymphocyte subsets in PBMC
were identiﬁed by ﬂow cytometry. 5 × 105 PBMC were ﬁxed
with1%paraformaldehydeandstainedwith5ulFITCorPE-
conjugatedmonoclonal antibody againstCD4orCD8(Anti-
genix America, Franklin Square, NY), or 10ul FITC or PE-
conjugated anti-CD20 (Becton-Dickinson, Mountain View,
CA). Relevant isotype controls were included. Samples were
analyzed on a FACScan ﬂow cytometer (Becton-Dickinson),
and data were processed using Becton-Dickinson Cell Quest
software.
Fixed PBMC that had been already stained with PE-
CD20,PE-CD4,orPE-CD8werealsostainedforsurfaceFasL
using puriﬁed antibody against FasL (NOK2) [21] followed
by FITC-conjugated goat-anti-mouse IgG. Labeled isotypeMaria S. Salvato et al. 7
control(IgG2a)wasincluded.PBMCwerelabeledforsurface
markers and then incubated for 20 minutes at 4◦C in PBS
that contained 20ug/mL of 7-AAD (Sigma, St. Louis MO).
7-AAD staining was chosen because it is an early indication
of cell death that does not interfere with other lymphocyte
markers and allows exclusion of cell debris [56]. Samples
were washed in PBS + 2% FBS containing 20ug/mL of non-
ﬂuorescentactinom ycinD(AD ,Sigma)andﬁx edinthesame
buﬀer containing 1% paraformaldehyde. Samples were ana-
lyzed 15 minutes later (10,000 events per sample) using the
FL-3 channel to detect 7-AAD staining.
4.6. Virusburdenassays
Virus RNA loads were determined by SIVmac RNA b-DNA
assays conducted by Bayer Diagnostics (Emeryville, CA) and
reported as copies of SIVmac RNA per mL of EDTA plasma.
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